Y-mAbs Therapeutics, Inc.
NASDAQ:YMAB
8.28 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
---|---|---|---|---|---|---|---|---|
Revenue
| 84.819 | 65.267 | 34.897 | 20.75 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 11.416 | 7.567 | 2.514 | 2.203 | 0.166 | 0.029 | 0 | 0 |
Gross Profit
| 73.403 | 57.7 | 32.383 | 18.547 | -0.166 | -0.029 | 0 | 0 |
Gross Profit Ratio
| 0.865 | 0.884 | 0.928 | 0.894 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 54.219 | 91.572 | 93.245 | 93.697 | 63.492 | 34.269 | 14.307 | 13.855 |
General & Administrative Expenses
| 0 | 0 | 0 | 44.785 | 19.512 | 8.961 | 4.937 | 3.184 |
Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 44.856 | 60.939 | 54.571 | 44.785 | 19.512 | 8.961 | 4.937 | 3.184 |
Other Expenses
| 0 | 0 | 62.01 | -2.203 | 0 | -0.044 | 0.083 | -0.018 |
Operating Expenses
| 99.075 | 152.511 | 147.816 | 138.482 | 83.004 | 43.23 | 19.244 | 17.039 |
Operating Income
| -25.672 | -94.811 | -115.433 | -119.935 | -83.004 | -43.23 | -19.244 | -17.039 |
Operating Income Ratio
| -0.303 | -1.453 | -3.308 | -5.78 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 4.806 | -0.757 | 60.158 | 0.598 | 1.976 | -0.044 | 0.083 | -0.018 |
Income Before Tax
| -20.866 | -95.568 | -55.275 | -119.337 | -81.028 | -43.274 | -19.161 | -17.057 |
Income Before Tax Ratio
| -0.246 | -1.464 | -1.584 | -5.751 | 0 | 0 | 0 | 0 |
Income Tax Expense
| 0.561 | 0.757 | 1.07 | -0.994 | -2.142 | -0.044 | -19.244 | -17.039 |
Net Income
| -21.427 | -96.325 | -56.345 | -118.343 | -78.886 | -43.274 | -19.161 | -17.057 |
Net Income Ratio
| -0.253 | -1.476 | -1.615 | -5.703 | 0 | 0 | 0 | 0 |
EPS
| -0.49 | -2.2 | -1.3 | -2.95 | -2.24 | -1.5 | -0.58 | -0.51 |
EPS Diluted
| -0.49 | -2.2 | -1.3 | -2.95 | -2.24 | -1.5 | -0.58 | -0.51 |
EBITDA
| -25.672 | -94.729 | -54.493 | -119.539 | -82.838 | -43.201 | 0.083 | -0.018 |
EBITDA Ratio
| -0.303 | -1.453 | -3.308 | -5.674 | 0 | 0 | 0 | 0 |